Gene tests for aggressive breast cancer set to enter market

Monogram Biosciences announced Tuesday that its HERmark breast cancer assay, which is designed to detect an aggressive form of the disease by measuring protein levels of the HER2 gene, will be launched on July 15. Invitrogen Corp. has obtained FDA approval for SPOT-Light, a test that can count copies of the HER2 gene to identify which breast cancer patients are likely to respond to Genentech's Herceptin.

View Full Article in:

Wall Street Journal (tiered subscription model), The · American City Business Journals · Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA